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Introduction {#sec005}
============

Incidence rates of aortic grafts infection in patients after primary aortic surgery in the current endovascular era is considerable \[[@pone.0230234.ref001]\]. Major aortic graft infection is a life-threatening complication with high mortality and morbidity rates \[[@pone.0230234.ref002],[@pone.0230234.ref003]\]. One of the most effective treatment modality of this devastating complication is the reoperation with replacement of an infected prosthesis by a cold-stored \[[@pone.0230234.ref004]\] or cryopreserved arterial allograft \[[@pone.0230234.ref005]\].

The recovery techniques of arterial allografts and subsequent cold-stored or cryopreservation/thawing protocols published by large vascular centers are very inhomogeneous \[[@pone.0230234.ref006],[@pone.0230234.ref007]\]. The different properties of storage solutions, variation in cold ischemic time prior to implantation (cold-stored allografts) or cryopreservation, different freezing and thawing protocols are used worldwide \[[@pone.0230234.ref004]--[@pone.0230234.ref006]\]. All these aspects can influence the final quality of implanted arterial allografts and caused significant differences in the early and late graft-related complications \[[@pone.0230234.ref006]\].

In the Czech Republic, the cold stored arterial allografts are used as a substitute for infected vascular prosthesis since middle 1990s \[[@pone.0230234.ref007]\]. Both solid organ and cold-stored arterial transplantation programs are governed by the same legislation and managed by the "Transplantation Coordination Centre of the Czech Republic". Therefore, the cold-stored arteries obtained during multi-organ recovery from braindead donors are stored in organ conservation solutions and must be transplanted to the patient included in the special "waiting list" within 48 hours after recovery \[[@pone.0230234.ref008]\].

However, cold-stored allografts were not in sufficient abundance for all the patients on the waiting list. Therefore, the clinical cryopreserved arterial transplantation program was started in 2011. All of arterial allografts included to the national program are processed exclusively in the Tissue Bank of The University Hospital Hradec Kralove under new standardized cryopreservation/slow thawing protocol \[[@pone.0230234.ref009]\].

At the present time there are two waiting list for patients indicated for arterial transplantation in the Czech Republic. The inclusion of each patient for cold-stored or cryopreserved arterial waiting list is the preference of indicating surgeon \[[@pone.0230234.ref009]\].

The experimental and clinical studies revealed strong antigenicity of both cold-stored and cryopreserved allografts, respectively \[[@pone.0230234.ref010],[@pone.0230234.ref011]\]. This immunogenicity is responsible for late graft-related complication presented as graft dilatation, rupture or thrombosis \[[@pone.0230234.ref012]\]. In addition, this immunogenicity is influenced by all procedure steps in their pretransplant history \[[@pone.0230234.ref010]\].

Therefore the aim of our study was:

1.  to transfer all steps of the new national standardized clinical cryopreservation/slow thawing protocol to the experimental settings,

2.  to study acute immune reaction of rats recipients of cryopreserved arterial grafts treated by this protocol,

3.  to compare the data of current cryopreservation/slow thawing experiment to data obtained previously by our cold-storage rat experiment to study the differences in immunogenicity of both cryopreserved and cold-stored aortal allografts, respectively.

Material and methods {#sec006}
====================

Ethics statement {#sec007}
----------------

Principles of laboratory animal care were followed, and applicable national laws observed during the study. The study protocol was approved by the Committee on 1. Medical faculty of Charles University in Prague (1.LF 563/13, MSMT-14808/2014-6).

Animals {#sec008}
-------

Male Brown-Norway rats (BN) (RT1^n^) (N = 3) weighting 203--217 g were used as donors of abdominal aortal allografts, and male Lewis rats (LEW) (RT1^l^) (N = 3) weighting 248--254 g were used as donors of abdominal aortal isografts, respectively. The recipient animals of cryopreserved aortal grafts (male Lewis rats (LEW) (RT1^l^) were divided into two groups. Group CRYO-ISO was that of cryopreserved isografts (LEW to LEW, N = 6, weighting 191--250 g), group CRYO-ALLO was that of cryopreserved allografts (BN to LEW, N = 6, weighting 193--245 g).

Animals were obtained from Charles River, Germany and maintained according to the National Institute of Health guidelines. Each transplanted animal was housed in a separate cage during the entire 30-day follow-up period.

Operative procedure {#sec009}
-------------------

All aspects of orthotopic abdominal aortic transplantation was described in details in our previous publications \[[@pone.0230234.ref013],[@pone.0230234.ref014]\]. The cryopreserved aortal grafts in recent experiment were transplanted by the same anesthesiological and surgical techniques used previously in our cold-stored aortal grafts experiment. Both experiments were supervised by the same principal investigator (I.M.). Briefly, a 2--2.5 cm long segment of the infrarenal aorta was excised, prepared and stored in accordance to cryopreservation protocol. Cryopreserved aortal grafts were implanted orthotopically into the recipient\`s infrarenal aorta after a midline laparotomy using a 10/0 mono-filament interrupted suture. No anticoagulants or anti-platelet drugs were used in recipients during the 30-day follow-up period.

Protocol of cryopreservation {#sec010}
----------------------------

The new clinical cryopreservation/slow thawing protocol was modified to experimental operating room conditions of Institute of Physiology of 1^st^ Medical faculty at the Charles University in Prague.

The all donor animals of each experimental group (CRYO-ISO (N = 3) and CRYO-ALLO (N = 3) were operated at once. Each abdominal aortal graft was flushed after the recovery with 2 ml of Custodiol solution (Custodiol®, Dr. Franz Köhler Chemie GmbH, Germany) containing 100 IU/ml of heparin and placed into 10 ml of pre-cooled Custodiol solution, thereafter. Each graft was stored at the temperature of melting ice in closed sterile certified plastic jars (Medfor 250 ml Farnborough, UK) until finalization of all donor´s operations. Thereafter, the aortal grafts were put into double sterile disposable plastic bags (CryoMACS Freezing Bag 500, Miltenyi Biotec GmbH, Germany) containing 25ml of pre-cooled 6% solution of hydroxyethylstarch m.w. 130.000 Da (Voluven 6%, Fresenius Kabi, Germany). No antibiotics were added. The content of the bag was subsequently mixed with pre-cooled 20% dimethylsulfoxide (DMSO) (WAK ChemieMedical GmbH, Germany) in the 6% hydroxyethylstarch solution (Voluven 6%, Fresenius Kabi, Germany) and each bag was closed by sealing at the sealing machine (STERISEAL B 83-R, Cevor s.r.o., Troubsko u Brna, Czech Republic). The bags were put into outer metal cassette (ST 100, Consarctic GmbH, Schölkrippen, Germany) and stored at the temperature of melting ice until the beginning of freezing process. The controlled--rate freezing by the rate of -1K/min to -90°C and -5K/min to -150°C was performed at the programmable freezer (Kryo-10, Planer Biomed, Sunbury on Thames, England). After completion of freezing process, the cassettes were transferred in liquid nitrogen vapour phase to the Tissue Establishment of the Institute of Haematology in Prague. The grafts were stored in this institution in liquid nitrogen vapour phase by temperature of -190°C until the day of implantation.

Protocol of thawing {#sec011}
-------------------

The cassettes with aortal grafts were transported at the day of implantation in liquid nitrogen vapour phase from the Tissue Establishment to the operating room of Institute of Physiology. The cassettes were removed from the shipper in the operating room and placed for about 60 minutes into a refrigerator with temperature of +4°C and then were kept for about 30 minutes by the room temperature. Subsequently, the aortal grafts were removed from the bag and each graft was divided into two pieces of an identical length to be used in two rat recipients. After dividing each aortal graft was stored separately in 10 ml of Custodiol solution in the refrigerator with temperature of +4°C until the beginning of anastomosis in the recipient animal. No antibiotics were added.

Time-periods of cryopreservation and thawing {#sec012}
--------------------------------------------

The whole process of aortal recovery, cryopreservation, storage, thawing and transplantation was divided into the six time-periods. The duration of each time-period was measured for each aortal graft separately. Detailed definitions and duration of each time--period of the cryopreservation/slow thawing protocol for each experimental group are summarized in [Table 1](#pone.0230234.t001){ref-type="table"}. The individual data per aortal graft are given in [S1 Table](#pone.0230234.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0230234.t001

###### Time-periods of the cryoconservation/slow thawing procedure.

![](pone.0230234.t001){#pone.0230234.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Time periods   Cryopreserved grafts                                                                                                                                                                                                                                                      
  -------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------
  1              PRE-FREEZING CIT\      Time period between aortal clamp in the donor animal and insertion of aortal grafts to DMSO solution. Aortal grafts were stored in Custodiol solution at the temperature of melting ice during this period.   03:12 hours (min 02:54, max 03:28)   03:31 hours (min 01:23, max 04:45)
                 (cold ischemic time)                                                                                                                                                                                                                                                      

  2              DMSO time              Time period between insertion of aortal grafts to DMSO solution and start of cryoconservation at the programmable freezer.                                                                                    00:40 hours (min 00:38 max 00:42)    00:38 hours (min 00:19, max 00:48)

  3              CRYO time              Time period between the start of cryoconservation of aortal grafts at the programmable freezer and insertion of cassetes to liquid nitrogen                                                                   02:38 hours                          02:38 hours

  4              NITROGEN time          Time period between insertion and removal of cassetes out of liquid nitrogen.                                                                                                                                 172,6 days (min 171, max 176)        179,3 days (min 176, max 181)

  5              THAWING time           Time period between removal of cassetes out of liquid nitrogen vapour phase and insertion of aortal grafts to Custodiol solution.                                                                             01:33 hours (min 01:10, max 01:45)   01:25 hours (min 01:10, max 01:33)

  6              POST-THAWING CIT\      Time period between insertion of aortal grafts to Custodiol solution and reperfusion of aortal graft in recipient animal.                                                                                     02:00 hours (min 00:58, max 03:27)   04:53 hours (min 02:26, max 07:07)
                 (cold ischemic time)                                                                                                                                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The process of recovery, cryoconservation, storage, thawing and transplantation of cryopreserved aortal grafts was divided into six defined and measured time periods.

CRYO-ISO---cryopreserved isografts

CRYO-ALLO---cryopreserved allografts

The total cold ischemic time of cryopreserved aortal grafts (pre-freezing + post-thawing cold ischemic time) was 313±62 minutes for isografts and 504±198 minutes for allografts, respectively. No statistical difference was observed between both groups.

Blood samples {#sec013}
-------------

Blood samples for determination of donor specific anti-MHC Class I and II antibodies on day 0, and day 30 in all groups were collected by orbital sinus puncture as described previously \[[@pone.0230234.ref013]\].

Aortal grafts explantation on day 30 {#sec014}
------------------------------------

After the blood samples collection (see above) a midline re-laparotomy was performed in anaesthetized animals. Aortal grafts were excised after the administration of heparin (100 IU/kg). The animals were then euthanized by intracaval administration of a lethal dose of thiopental \[[@pone.0230234.ref013]\].

Parameters under study {#sec015}
----------------------

### Histological and immunohistological analysis of explanted aortal grafts {#sec016}

All histological and immunohistological techniques used were identical to those used in cold-stored aortal grafts experiment \[[@pone.0230234.ref013]\]. In short, the sections for histological and immunohistological analysis were taken from the midportion of the graft. The sections were stained with a Hematoxylin-Eosin and Van Gieson with elastica stain and analyzed using Olympus DP-Soft software. Medial thickness were measured up to 10 locations in each section. The mean value and standard deviation (SD) (mean ± SD) were calculated for each aorta as well as animal group. The specific antibodies for detection of endothelial cells, CD4+, CD8+, Lewis MHC class II+ cells, immunoglobulins G were used for immunohistological examination of aortal grafts. Detailed specifications of antibodies and immunohistological techniques are summarized in [Table 2](#pone.0230234.t002){ref-type="table"}.

10.1371/journal.pone.0230234.t002

###### Detailed specifications of antibodies and immunohistological techniques used.

![](pone.0230234.t002){#pone.0230234.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Histology of aortal grafts                                 Hematoxilin eosin                                                                                                    
  ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Immunohistology of aortal grafts                           CD4+ cells                                                                                                           Primary antibody: anti-CD4\
                                                                                                                                                                                  (W3/25, Cymbus Biotechnology LTD, Hampshire, UK)\
                                                                                                                                                                                  Secondary antibody: Histofine® Simple Stain Rat MAX PO (Nichirei Biosciences Inc., Japan)\
                                                                                                                                                                                  Detection system: Dako Liquid DAB+ Substrate-Chromogen System (Dako Denmark A/S, Glostrup, Denmark)

  CD8+ cells                                                 Primary antibody: anti-CD8\                                                                                          
                                                             (OX-8, Cymbus Biotechnology LTD, Hampshire, UK)\                                                                     
                                                             Secondary antibody: Histofine® Simple Stain Rat MAX PO (Nichirei Biosciences Inc., Japan)\                           
                                                             Detection system: Dako Liquid DAB+ Substrate-Chromogen System (Dako Denmark A/S, Glostrup, Denmark)                  

  Endothelial cells                                          Primary antibody: anti-Von Willebrand factor\                                                                        
                                                             (Dako Denmark A/S, Glostrup, Denmark)\                                                                               
                                                             Secondary antibody: Histofine® Simple Stain Rat MAX PO (Nichirei Biosciences Inc., Japan)\                           
                                                             Detection system: Dako Liquid DAB+ Substrate-Chromogen System (Dako Denmark A/S, Glostrup, Denmark)                  

  Lewis MHC class II+ cells                                  Primary antibody: anti RT1.B^u^\                                                                                     
                                                             (MRC-OX3, Cedarlane Laboratories Ltd., Burlington, Canada)\                                                          
                                                             Secondary antibody: horse anti mouse antibody (Vector Lab, Burlingame, USA)\                                         
                                                             Detection system: R.T.U. Vectastain Elite ABC\                                                                       
                                                             Reagent (Vector Lab, Burlingame, USA)                                                                                

  Immunoglobulines G                                         Primary antibody: anti rat IgG cunjugated with fluoroscein isothianate (Chemicon International Inc.,Temecula, USA)   

  Flow cytometry analysis of aortal grafts recipients sera   MHC Class I                                                                                                          Primary antibody: anti-RT1.Ac\
                                                                                                                                                                                  (OX-27, Acris Antibodies GmbH, Herford, Germany)\
                                                                                                                                                                                  Secondary antibody: PE-Cy7-Streptavidin (BD Biosciences, Heidelberg, Germany)

  MHC Class II                                               Primary antibody: anti-RT1.D\                                                                                        
                                                             (OX-17, BD Biosciences, Heidelberg, Germany)\                                                                        
                                                             Secondary antibody: PE-Cy7-Streptavidin (BD Biosciences, Heidelberg, Germany)                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Specification of monoclonal and polyclonal antibodies used for histological analysis of aortal grafts (30 days after transplantation) and flow cytometry analysis of recipients sera (pretransplant and 30 days after transplantation, respectively).

The slides were scored in a blinded fashion. CD4+, CD8+ and Lewis MHC class II+ cells were counted at 10 locations at x1000 magnification. The cellularity was defined as the mean value of the cells counted.

### Flow cytometry analysis of blood sample {#sec017}

In vitro binding of cryopreserved aortal grafts recipient sera to quiescent Brown-Norway splenocytes was determined by flow cytometry. All procedures were identical to those used previously in cold-stored aortal grafts experiment \[[@pone.0230234.ref015]\]. Detailed specifications of antibodies used are summarized in [Table 2](#pone.0230234.t002){ref-type="table"}.

### Statistical analysis {#sec018}

The values in the text and tables are expressed as the mean±standard deviation (SD). Comparisons of parameters under study between experimental groups (total cold ischemic time, tunica media thickness, CD4+, CD8+, MHC II+ cells, anti MHC I and anti MHC II antibodies) were performed using the analysis of variance (ANOVA), followed by the Tukey HSD Multiple Comparisons test. All analyses were conducted in Stata (version 12.1).

Results {#sec019}
=======

Animals {#sec020}
-------

Twelve aortal grafts were successfully transplanted. All recipient animals survived the whole 30 day follow-up period.

Histology and immunohistology of cryopreserved isografts and allografts on day 30 posttransplant {#sec021}
------------------------------------------------------------------------------------------------

The both isografts and allografts explanted on day 30 posttransplant showed regular morphology of aortal wall with clear differentiation of all three basic anatomical layers ([Fig 1A--1F](#pone.0230234.g001){ref-type="fig"}). The luminal surface of tunica intima was covered by a monolayer of endothelial cells. No signs of intimal hyperplasia and no Lewis MHC group II positive cells infiltration of intimal layer were detected. The medial layer of both isografts and allografts showed no signs of necrosis or immunoglobulin G depositions ([Fig 1F](#pone.0230234.g001){ref-type="fig"}). Indeed, no statistical difference was observed in the thickness of tunica media of both groups ([Table 3](#pone.0230234.t003){ref-type="table"}). The adventitial infiltration with MHC class II+ cells of Lewis origin, CD4+ and CD8+ cells was significantly higher in aortal allografts ([Fig 1D and 1E](#pone.0230234.g001){ref-type="fig"}) compared to isografts ([Fig 1A and 1B](#pone.0230234.g001){ref-type="fig"}) ([Table 3](#pone.0230234.t003){ref-type="table"}).

![**a,b,c,d,e,f. Representative light microscopic histological features of both isografts (a,b,c) and allografts (d,e,f) treated by our new cryoconservation/slow thawing protocol and obtained on day 30 following transplantation.** Both isografts (Fig 1A, 1B, and 1C) and allografts (Fig 1D, 1E and 1F) showed clear differentiation of all three basic anatomical layers with no signs of intimal hyperplasia. No signs of medial layer destruction with immunoglobulins G deposition was detected in either isografts (Fig 1C) or allografts (Fig 1F). The adventitial infiltration of cryopreserved allografts by CD4+ (Fig 1D) and CD8+ cells (Fig 1E) (stained brown) was significantly higher compared to isografts (Fig 1A and 1B). Fig 1A and 1D --Anti-CD4 antibody, original magnification x 100, positive cells stained brown. Fig 1B and 1E --Anti-CD8 antibody, original magnification x 100, positive cells stained brown. Fig 1C and 1F --Anti-IgG fluorescein isothiocyanate-conjugated antibody, original magnification x 100.](pone.0230234.g001){#pone.0230234.g001}

10.1371/journal.pone.0230234.t003

###### Histological and immunohistological parameters of cryopreserved aortal grafts under study on day 30 posttransplant.

![](pone.0230234.t003){#pone.0230234.t003g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                  CRYOGRAFTS on 30 POD                                                     
  ------------------------------- ---------------------- ------------------------------------------------- ------------------------------------------------
  Intimal layer                   Endothelial layer      \+                                                \+

  Intimal hyperplasia             \-                     \-                                                

  \                               SMC necrosis           \-                                                \-
  Medial layer                                                                                             

  IgG deposition                  \-                     \-                                                

  Medial thickness (mikrometer)   79.3 ± 15.4            75.4 ± 14.9                                       

  \                               CD8+ cells             2.2 ± 2.7                                         6.9 ± 5.4[\*](#t003fn002){ref-type="table-fn"}
  Adventitial layer                                                                                        

  CD4+ cells                      3.9 ± 2.6              9.6 ± 6.5[\*](#t003fn002){ref-type="table-fn"}    

  LEW MHC class II+ cells         6.3 ± 4.4              20.7 ± 6.7[\*](#t003fn002){ref-type="table-fn"}   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

The rat aortal allografts processed in accordance with new clinical cryoconservation/slow thawing protocol showed normal anatomical structure of aortal wall with higher concentrations of immunocompetent cells in adventitial layer compared to isografts.

\* The total amounts of CD4+, CD8+ and Lewis MHC class II+ cells in adventitial layer of cryopreserved aortal allografts were significantly higher (P\<0.05) than those observed in cryopreserved aortal isografts

Serum anti-MHC Class I and Class II antibodies in recipients of cryopreserved aortal isografts and allografts {#sec022}
-------------------------------------------------------------------------------------------------------------

Pretransplant as well as day 30 sera from isografted animals showed no inhibition of fluorescence-labelled MHC class I and class II antibody binding to donor quiescent splenocytes.

Day 30 sera from allografted animals showed higher inhibition of fluorescence-labelled MHC class I and class II antibody binding to donor quiescent splenocytes compared to day 0 sera. However statistical significance (p\>0.05) was observed only by MHC class I antibodies ([Table 4](#pone.0230234.t004){ref-type="table"}).

10.1371/journal.pone.0230234.t004

###### Percentage of fluorescence-labelled MHC class I and MHC class II antibody binding to Brown-Norway splenocyte in the presence of sera of Lewis recipients of aortal iso- or allografts.

![](pone.0230234.t004){#pone.0230234.t004g}

  ---------------------------------------------------------------------------------------------------
                       MHC class I   MHC class II                                            
  -------------------- ------------- --------------------------------------------- --------- --------
  ISOGRATS\            111%±7%       97%±5%                                        90%±20%   98%±7%
  (CRYO-ISO, N = 6)                                                                          

  ALLOGRAFTS\          111%±22%      47±19%[\*](#t004fn001){ref-type="table-fn"}   101±42%   66±12%
  (CRYO-ALLO, N = 6)                                                                         
  ---------------------------------------------------------------------------------------------------

\* P\>0.05

Comparison of immunogenicity of rat aortal allografts treated by new clinical cryopreservation/slow thawing protocol to rat aortal allografts treated by clinical cold-storage protocol {#sec023}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The protocol used in the clinical program of cold-stored arterial allografts transplantation in the Czech Republic was modified to experimental operating room conditions and described in details in our previous publication \[[@pone.0230234.ref013]\]. The original core data of recent experiment were compared to historical data of our cold-stored allografts experiment \[[@pone.0230234.ref013]\]. Both experiments were supervised by the same principal investigator (I.M.).

The cold-stored allografts showed significant higher immunogenicity compared to cryopreserved allografts on day 30 posttranspant. The hyperplastic intima was infiltrated by recipient MHC class II+ cells and CD8+ cells. The medial layer showed signs of necrosis and deposition of immunoglobulins G and was significantly thinner (P\<0.05) compared to cryografts ([Fig 2](#pone.0230234.g002){ref-type="fig"}).

![**Representative histological features of cryopreserved (A) and cold-stored aortal allografts (B) on day 30 posttransplant. Immunofluorescent staining for immunoglobulins G with a fluorescein isothiocyanate-conjugated antibody.** The rats aortal allografts processed in accordance with cryoconservation/slow thawing protocol used in the Czech national "Cryopreserved vascular grafts program" (A) showed clear differentiation of all three basic anatomical layers with no intimal hyperplasia and no IgG deposition in the medial layer. The rats aortal allografts processed in accordance with clinical cold-storage protocol (B) showed significant signs of rejection in all three wall layer represented by intimal hyperplasia (white star), destruction of medial layer with massive deposition of IgG (white arrows) and massive adventitial infiltration with immunocompetent cells of host origin. Original magnification x 100. adventitia--Tunica adventitia media--Tunica media intima--Tunica media.](pone.0230234.g002){#pone.0230234.g002}

The adventitial layer of cold-stored allografts showed ten-fold higher infiltration by CD4+ and CD8+ cells when compared to cryopreserved allografts.

Day 30 recipient sera of both cryopreserved and cold-stored allografts showed significant higher inhibition of fluorescence-labelled MHC class I antibody binding to donor quiescent splenocytes compared to preoperative values. However, the statistically higher inhibition of fluorescence-labelled MHC class II antibody binding to donor quiescent splenocytes compared to preoperative values was observed only in recipients of cold-stored allografts.

Discussion {#sec024}
==========

The present study examined influence of the new standardized clinical cryoconservation/slow thawing protocol used in the Czech national "Cryopreserved vascular grafts program" on acute immunogenicity of cryopreserved aortal allografts in rats. This protocol allowed to process the aortal allografts by short pre-freezing cold ischemia, controlled freezing process, slow thawing process and short post-thawing cold ischemia as well. Indeed, using this protocol the aortal allografts were stored in modern solid organ conservation solution during both cold ischemic periods.

The rat cryopreserved aortal allografts showed only very low signs of immune mediated destruction on day 30 posttranspant. Indeed, the arterial isografts treated by this protocol showed only very small inflammatory reaction in their wall as well. Contrary, aortal allografts treated by cold storage protocol showed statistically higher activation of recipient´s immune system with significant rejection changes in all three basic wall layers.

The most important issues of cryopreservation/thawing procedure during the pre-freezing period are both properties of conservation solution and duration of cold ischemia, respectively \[[@pone.0230234.ref010]\]. It was reported that prolonged cold-ischemia induced substantial damage to the arterial wall and that the endothelial cells are most susceptible to cold ischemia \[[@pone.0230234.ref016]\]. Indeed, Knight et al. have shown in rats, that 24 hours of cold ischemia induced vascular disease in both iso- and allografts at 4 weeks after transplantation \[[@pone.0230234.ref017]\].

In our experiment, pre-freezing ischemic times of aortal allografts were about 3--4 hours. Indeed, the cryopreserved grafts were stored immediately after recovery in pre-cooled organ preservation solution. It is very likely that this very short cold-ischemic time resulted both in significantly lower endothelial damage of cryopreserved grafts prior the transplantation and in minimal intimal reaction observed on day 30 posttransplant, respectively.

The fast warming at 37°C in a water bath is mentioned in the most of recent published clinical works as the standard thawing method of cryopreserved arterial allografts \[[@pone.0230234.ref002]\]. However, recent experimental studies confirmed high damage level of rapidly thawed vascular tissues \[[@pone.0230234.ref018],[@pone.0230234.ref019]\]. Contrary to this the slow thawing protocol diminished the immune response induced by cold-stored rat arterial allografts and improved their behavior after implantation \[[@pone.0230234.ref010]\]. However, this protocol is not suitable for clinical condition in operating room during the preparation of cryopreserved aortal grafts for implantation. First, the cryopreserved arterial grafts were transferred from storage tank to the freezer where they were thawed according to a slow thawing program to room temperature at a warming rate of 1°C/minute. Second, the cryoprotectant was removed gradually in tapered dilutions. According to our clinical protocol, the cassetes with cryopreserved grafts are thawed in a normal refrigerator within 2 hours and they are stored thereafter in the pre-cooled conservation solution until implantation \[[@pone.0230234.ref008]\].

Upregulation of major histocompatibility antigens expression by both ischemic and cryopreservation/fast thawing injury with appearance of microfractures may increase the immunogenicity of arterial allografts \[[@pone.0230234.ref018]\]. These antigens trigger strong donor specific anti-MHC Class I and anti-MHC Class II alloantibody production which drives the apoptosis of SMCs with medial layer destruction \[[@pone.0230234.ref020]\]. The medial layer of aortal allografts treated by our new cryoconservation/slow thawing protocol showed no signs of destruction detected by light microscopy, no IgG deposition and no shrinkage compared to isografts 30 days posttransplant. However, in this work we didn´t use transmission electron microscopy to detect microfractures in aortal wall.

The statistically higher concentration of donor specific antibodies compared to preoperative values in recipients of cryopreserved allografts we observed only by anti MHC class I but not by anti MHC class II antibodies. MHC class II antigens are expressed on immunologically activated endothelial and smooth muscle cells \[[@pone.0230234.ref021]\]. So it is possible that our cryopreservation/slow thawing protocol inhibited upregulation of major histocompatibility antigens expression in medial smooth muscle cells during the 30 day follow-up period. This hypothesis can be supported with no appearance of IgG clusters in medial layer of cryopreserved allografts on day 30 posttransplant as well. However, the effect of these serum anti MHC class I antibodies on immunological rejection of aortal allografts during the longer follow-up period is not clear.

The most significant limitation of this study is the comparison of current cryopreserved allografts data with historical cold-stored allografts data only. Recipients of cryografts were substantially smaller than the recipient of cold-stored allografts due to different ages of experimetal animals used in the two studies. However, the differences in the impact on aortal allograft rejection between both preservation protocols have been found to be much more pronounced than we expected. Therefore, further experiments with direct comparison of the two clinically used protocols are needed to confirm our observations.

Conclusion {#sec025}
==========

In conclusion, the present study considered that histological features of rat aortal allografts treated by our new cryopreservation/slow thawing clinical protocol did not show significant differences compared to isograft 30 day following transplantation. In addition, significantly lower immunogenicity of cryopreserved allografts compared to historical data of cold-stored allografts treated by clinical protocol was observed. However, other experiments are needed to confirm this effect. In the end, their positive results can influence the indication criteria and immunosuppressive therapy in the Czech national "Cryopreserved vascular grafts program" in the future.

Supporting information {#sec026}
======================

###### The individual data per aortal graft of all measured time-periods of the cryoconservation/slow thawing procedure.

(XLSX)

###### 

Click here for additional data file.

10.1371/journal.pone.0230234.r001
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Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Prof. Raffaele Serra, M.D., Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. To comply with PLOS ONE submission requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

Additional Editor Comments (if provided):

The manuscript is potentially interesting for the journal. Please see reviewers\' suggestions and amend your manuscript accordingly.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The overall goal of this study aims to determine if a new cryopreservation and slow thawing protocol for aortal grafts elicits an acute immune response and to compare this response to the current standard \"cold-storage\" protocol. Given the urgent clinical need for additional allografts for patients on the waiting list, the rationale for this study is excellent and provides valuable data toward the development of a protocol to be tested in humans. The results suggest that their new protocol for storing allografts prior to use reduces immunogenicity which could lead to improved functional results.

However, the comparison of the CRYO groups to the COLD groups needs some additional description and comparison to ensure that their conclusion is accurate. First, the authors state in the introduction that protocols used in different center vary considerably and can influence the end results of the allografts. In this regard, Table 1 aims to compare the key steps in the protocols between the CRYO and COLD protocols. This table needs to have more details included or the details need to be added to the body of the manuscript. First, the units of time are not included (minutes, hours, etc.) other than the time recorded in days. Second, since there are only a few rats in each group, the individual data per rat should be included in the manuscript, either as a separate table or in supplemental material. This could be especially important for the time periods that have a wide range of results such as the pre-freezing CIT. The range for CRYO-ALLO is between 1:23 and 4:45 which could influence the final quality and would need to be further refined in developing a protocol to translate to humans. Similarly, post-thawing also has a similarly wide range of results. Were the animals with the shortest or longest times the same in both the pre-freezing and post-thawing? Is there any correlation to the histological and immunohistological results presented in Table 3 with the total time of the procedure presented in Table 1? Was there an expected time for each time-period of the cryopreservation and thawing process and any plan for inclusion/exclusion of results if the expected time was exceeded?

It appears that the results for the COLD protocol were not collected as part of this study but results from this study compared to results previously published in 2007. This comment is based on the the sentence that begins on page 7, line 134. What controls were used to ensure that the surgical procedures used to collect the tissues and graft the procedures were comparable between studies performed many years apart? In addition, it appears that the CRYO rats were substantially smaller than the COLD rats, presumably due to different ages being used in the two studies. Age should be included in the results and any implications of age related responses should be discussed in the manuscript.

It needs to be made very clear if the COLD results being used to compare the CRYO results are previously published or replicated in the current study. The results section indicates that 24 aortal grafts were transplanted which suggests that all were done as part of the current study. However, there were two COLD animals that died, similar to the results in the 2007 published paper. The PLOS ONE instructions clearly states that results that have been previously published, in whole or in part, are not accepted, so it is critical to be clear if the COLD results are new or previously published.

There are two sections in the results labelled \"Histology and immunohistology of cryopreserved and cold-store aortal allografts on day 30 posttransplant\" so some reorganization is needed for clarity. The histological results in Figure 1 need to have a figure legend included to orient the reader to the images and interpretation of the results. In addition, a comparison between CRYO-ALLO and CRYO-ISO would complement these results well. The methods indicate that both intimal and medial thickness were measured (page 13, line 251-252) but only medial thickness was reported in table 4. Intimal thickness should be presented.

Finally, there are some typos that should be corrected (e.g. immunoglobulines, nitrogene). A proof read for standard English is also suggested.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Reviewer of PLOSone,

I would like to send our responses to your review of our Article: Influence of the New Standardized Clinical Cryopreservation/Slow Thawing Protocol on Immunogenicity of Arterial Allografts in Rats

I would like to thank you for your review comments that helped us to improve our publication.

Yours faithfully

Ivan Matia

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The overall goal of this study aims to determine if a new cryopreservation and slow thawing protocol for aortal grafts elicits an acute immune response and to compare this response to the current standard \"cold-storage\" protocol. Given the urgent clinical need for additional allografts for patients on the waiting list, the rationale for this study is excellent and provides valuable data toward the development of a protocol to be tested in humans. The results suggest that their new protocol for storing allografts prior to use reduces immunogenicity which could lead to improved functional results.

However, the comparison of the CRYO groups to the COLD groups needs some additional description and comparison to ensure that their conclusion is accurate. First, the authors state in the introduction that protocols used in different center vary considerably and can influence the end results of the allografts. In this regard, Table 1 aims to compare the key steps in the protocols between the CRYO and COLD protocols. This table needs to have more details included or the details need to be added to the body of the manuscript. First, the units of time are not included (minutes, hours, etc.) other than the time recorded in days.

Units were added into the Table 1

Table 1. Time-periods of the cryoconservation/slow thawing procedure.

Second, since there are only a few rats in each group, the individual data per rat should be included in the manuscript, either as a separate table or in supplemental material.

The individual data per rat were added in suplemental material.

This could be especially important for the time periods that have a wide range of results such as the pre-freezing CIT. The range for CRYO-ALLO is between 1:23 and 4:45 which could influence the final quality and would need to be further refined in developing a protocol to translate to humans. Similarly, post-thawing also has a similarly wide range of results. Were the animals with the shortest or longest times the same in both the pre-freezing and post-thawing?

The total cold ischemic time of cryopreserved aortal grafts (pre-freezing + post-thawing cold ischemic time) was 313±62 minutes for isografts and 504±198 minutes for allografts, respectively. No statistical difference was observed between both groups.

This information was added to the manuscript.

Is there any correlation to the histological and immunohistological results presented in Table 3 with the total time of the procedure presented in Table 1?

No, we have seen no correlation to the total time oft he procedure in Table 1.

Was there an expected time for each time-period of the cryopreservation and thawing process and any plan for inclusion/exclusion of results if the expected time was exceeded?

No there was no expected time for any time-period.

All steps and time intervals of presented experimental protocol are in accordance with our clinical protocol. However, times of pre-freezing and post-thawing cold ischemia vary widely in clinical conditions. In this experiment we achieved shortening of both cold ischemic times.

Špaček M, Měřička P, Janoušek L, Štádler P, Adamec M, Vlachovský R, et al. Current vascular allograft procurement, cryopreservation and transplantation techniques in the Czech Republic. Adv Clin Exp Med. 2019;28: 529--534.

Moreover the information about total ischemic time in both groups was added as follows:

The total cold ischemic time of cryopreserved aortal grafts (pre-freezing + post-thawing cold ischemic time) was 313±62 minutes for isografts and 504±198 minutes for allografts, respectively. No statistical difference was observed between both groups.

It appears that the results for the COLD protocol were not collected as part of this study but results from this study compared to results previously published in 2007. This comment is based on the the sentence that begins on page 7, line 134. What controls were used to ensure that the surgical procedures used to collect the tissues and graft the procedures were comparable between studies performed many years apart?

Yes the results for the COLD protocol were collected as part of the previously published study. This information is newly mentioned in the text as follows:

The original core data of recent experiment were compared to historical data of our cold-stored allografts experiment.\[13\]

The cryopreserved aortal grafts in recent experiment were transplanted by the same anesthesiological and surgical techniques used previously in our cold-stored aortal grafts experiment. Both experiments were supervised by the same principal investigator (I.M.).

Moreover, the third aim of our study was changed as follows:

3\. to compare the data of current cryopreservation/slow thawing experiment to data obtained previously by our cold-storage rat experiment to study the differences in immunogenicity of both cryopreserved and cold-stored aortal allografts, respectively

In the new version of our manuscript, there are no numerical data published previously.

In addition, it appears that the CRYO rats were substantially smaller than the COLD rats, presumably due to different ages being used in the two studies. Age should be included in the results and any implications of age related responses should be discussed in the manuscript.

The limitation section was added to he manuscript as follows:

The most significant limitation of this study is the comparison of current cryopreserved allografts data with historical cold-stored allografts data only. Recipients of cryografts were substantially smaller than the recipient of cold-stored allografts due to different ages being used in our two studies. However, the differences in the impact on aortal allograft rejection between both preservation protocols have been found to be much more pronounced than we expected. Therefore, further experiments with direct comparison of the two clinically used protocols are needed to confirm our observations.

It needs to be made very clear if the COLD results being used to compare the CRYO results are previously published or replicated in the current study. The results section indicates that 24 aortal grafts were transplanted which suggests that all were done as part of the current study. However, there were two COLD animals that died, similar to the results in the 2007 published paper. The PLOS ONE instructions clearly states that results that have been previously published, in whole or in part, are not accepted, so it is critical to be clear if the COLD results are new or previously published.

The information on the COLD results has been extended and explaned in the text as mentioned above.

There are two sections in the results labelled \"Histology and immunohistology of cryopreserved and cold-store aortal allografts on day 30 posttransplant\" so some reorganization is needed for clarity.

The histology section was reorganized as follows:

Histology and immunohistology of cryopreserved isografts and allografts on day 30 posttransplant

The histological results in Figure 1 need to have a figure legend included to orient the reader to the images and interpretation of the results.

The new Figure 1 composed of six histological images was added:

Representative light microscopic histological features of both isografts (a,b,c) and allografts (d,e,f) treated by our new cryoconservation/slow thawing protocol and obtained on day 30 following transplantation.

The previous Figure 1 is now listed as Figure 2.The captions were added to the image.

In addition, a comparison between CRYO-ALLO and CRYO-ISO would complement these results well. The methods indicate that both intimal and medial thickness were measured (page 13, line 251-252) but only medial thickness was reported in table 4. Intimal thickness should be presented.

Table 3 compares now the results between CRYO-ALLO and CRYO-ISO group

Table 3. Histological and immunohistological parameters of cryopreserved aortal grafts under study on day 30 posttransplant.

Finally, there are some typos that should be corrected (e.g. immunoglobulines, nitrogene). A proof read for standard English is also suggested.

Corrected.
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Additional Editor Comments (optional):

amended manuscript is acceptable

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Most of the previous comments have been adequately addressed.

However, there is still a minor concern related to the time of each step and the potential impact on the overall results. The authors claim that there are no statistical differences but the number of samples might limit the finding of any statistical differences. The pre-freezing time, the post-thawing time, and the total time are all greater in the ALLO group compared to the ISO group. Are the post-thawing times statistically different between groups? It would be ideal to confirm that all aspects of the cryo protocol have been compared appropriately.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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